-
公开(公告)号：US20190127387A1
公开(公告)日：2019-05-02
申请号：US16091541
申请日：2017-04-06
发明人： Shaomeng Wang , Yangbing Li , Jiuling Yang , Angelo Aguilar , Bing Zhou , Jiantao Hu , Fuming Xu , Rohan Rej , Xin Han
IPC分类号： C07D487/10 , C07D401/04 , C07D401/14 , C07D417/14 , A61P35/00
摘要： The present disclosure provides compounds represented by Formula I-A: A1-L1-B1 I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.
-
公开(公告)号：US10759808B2
公开(公告)日：2020-09-01
申请号：US16091544
申请日：2017-04-06
发明人： Shaomeng Wang , Yangbing Li , Angelo Aguilar , Bing Zhou , Jiantao Hu , Fuming Xu , Chong Qin , Yang Hu , Weiguo Xiang , Rohan Rej , Jiuling Yang , Xin Han , Longchuan Bai , Chao-Yie Yang
IPC分类号： C07D401/04 , C07D487/10 , C07D401/14 , C07D487/04 , C07D495/14
摘要： The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
-
公开(公告)号：US20190169195A1
公开(公告)日：2019-06-06
申请号：US16093160
申请日：2017-04-06
发明人： Shaomeng Wang , Bing Zhou , Fuming Xu , Jiantao Hu , Longchuan Bai , Chao-Yie Yang
IPC分类号： C07D487/04 , A61P35/00 , C07K5/083
摘要： The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein B, R1, R5, Q1, Q″, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provids compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
-
公开(公告)号：US20220356192A1
公开(公告)日：2022-11-10
申请号：US17227641
申请日：2021-04-12
发明人： Shaomeng Wang , Yang Hu , Chong Qin , Fuming Xu , Jiantao Hu , Weiguo Xiang , Bing Zhou
IPC分类号： C07D495/14 , A61P35/00 , C07K5/06 , A61K45/06
摘要： The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
-
公开(公告)号：US10975093B2
公开(公告)日：2021-04-13
申请号：US16332544
申请日：2017-09-13
发明人： Shaomeng Wang , Yang Hu , Chong Qin , Fuming Xu , Jiantao Hu , Weiguo Xiang , Bing Zhou
IPC分类号： C07D495/14 , C07K5/06 , A61K45/06 , A61P35/00
摘要： The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
-
公开(公告)号：US20210002289A1
公开(公告)日：2021-01-07
申请号：US17007191
申请日：2020-08-31
发明人： Yangbing Li , Angelo Aguilar , Bing Zhou , Jiantao Hu , Fuming Xu , Chong Qin , Yang Hu , Weiguo Xiang , Rohan Rej , Jiuling Yang , Xin Han , Longchuan Bai , Chao-Yie Yang
IPC分类号： C07D487/10 , C07D401/04 , C07D401/14 , C07D487/04 , C07D495/14
摘要： The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
-
公开(公告)号：US20220411432A1
公开(公告)日：2022-12-29
申请号：US17462355
申请日：2021-08-31
发明人： Shaomeng Wang , Yangbing Li , Jiuling Yang , Angelo Aguilar , Bing Zhou , Jiantao Hu , Fuming Xu , Rohan Rej , Xin Han
IPC分类号： C07D487/10 , C07D401/04 , A61P35/00 , C07D401/14 , C07D417/14
摘要： The present disclosure provides compounds represented by Formula I-A: A1-L1-B1 I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.
-
公开(公告)号：US11466028B2
公开(公告)日：2022-10-11
申请号：US16332533
申请日：2017-09-13
发明人： Shaomeng Wang , Yang Hu , Chong Qin , Fuming Xu , Jiantao Hu , Bing Zhou , Zhuo Chen , Ester Fernandez-Salas , Longchuan Bai , Donna McEachern
IPC分类号： C07D498/14 , A61P35/02 , A61P35/04
摘要： The present disclosure provides compounds represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
-
公开(公告)号：US20210284657A1
公开(公告)日：2021-09-16
申请号：US16332533
申请日：2017-09-13
发明人： Shaomeng Wang , Yang Hu , Chong Qin , Fuming Xu , Jiantao Hu , Bing Zhou , Zhuo Chen , Ester Fernandez-Salas , Longchuan Bai , Donna McEachern
IPC分类号： C07D498/14 , A61P35/04 , A61P35/02
摘要： The present disclosure provides compounds represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
-
公开(公告)号：US20190263827A1
公开(公告)日：2019-08-29
申请号：US16332544
申请日：2017-09-13
发明人： Shaomeng Wang , Yang Hu , Chong Qin , Fuming Xu , Jiantao Hu , Weiguo Xiang , Bing Zhou
IPC分类号： C07D495/14 , A61P35/00
摘要： The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.023 秒)
